FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3157727129> ?p ?o ?g. }

• W3157727129 endingPage "1019" @default.
• W3157727129 startingPage "1007" @default.
• W3157727129 abstract "PurposeGiven the coronavirus disease 2019 (COVID-19) pandemic, there is a global urgency to discover an effective treatment for patients withthis disease. This study aimed to evaluate the effects of the widely used antiparasitic drug ivermectin on outcomes in patients with COVID-19.MethodsIn this randomized, double-blind clinical trial, patients with COVID-19 admitted to 2 referral tertiary hospitals in Mazandaran, Iran, were randomly divided into 2 groups: intervention and control. In addition to standard treatment for COVID-19, the intervention group received a single weight-based dose (0.2 mg/kg) of ivermectin; the control group received the standard of care. Demographic, clinical, laboratory, and imaging data from participants were recorded at baseline. Patients were assessed daily for symptoms and disease progression. The primary clinical outcome measures were the durations of hospital stay, fever, dyspnea, and cough; and overall clinical improvement.FindingsSixty-nine patients were enrolled (mean [SD] ages: ivermectin, 47.63 [22.20] years; control, 45.18 [23.11] years; P = 0.65). Eighteen patients (51.4%) in the ivermectin group and 18 (52.9%) in control group were male (P = 0.90). The mean durations of dyspnea were 2.6 (0.4) days in the ivermectin group and 3.8 (0.4) days in the control group (P = 0.048). Also, persistent cough lasted for 3.1 (0.4) days in the ivermectin group compared to 4.8 (0.4) days in control group (PP = 0.019). The mean durations of hospital stay were 7.1 (0.5) days versus 8.4 (0.6) days in the ivermectin and control groups, respectively (P = 0.016). Also, the frequency of lymphopenia decreased to 14.3% in the ivermectin group and did not change in the control group (P = 0.007).ImplicationsA single dose of ivermectin was well-tolerated in symptomatic patients with COVID-19, and important clinical features of COVID-19 were improved with ivermectin use, including dyspnea, cough, and lymphopenia. Further studies with larger sample sizes, different drug dosages, dosing intervals and durations, especially in different stages of the disease, may be useful in understanding the potential clinical benefits ivermectin. Iranian Registry of Clinical Trials identifier: IRCT20111224008507N3." @default.
• W3157727129 created "2021-05-10" @default.
• W3157727129 creator A5002948253 @default.
• W3157727129 creator A5015202852 @default.
• W3157727129 creator A5017719452 @default.
• W3157727129 creator A5031651486 @default.
• W3157727129 creator A5040224979 @default.
• W3157727129 creator A5053766617 @default.
• W3157727129 creator A5067263527 @default.
• W3157727129 creator A5084360723 @default.
• W3157727129 date "2021-06-01" @default.
• W3157727129 modified "2023-10-09" @default.
• W3157727129 title "Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-blind, Randomized, Controlled Clinical Trial" @default.
• W3157727129 cites W2773588431 @default.
• W3157727129 cites W2981366800 @default.
• W3157727129 cites W3006751003 @default.
• W3157727129 cites W3006882119 @default.
• W3157727129 cites W3008295344 @default.
• W3157727129 cites W3009828946 @default.
• W3157727129 cites W3010611713 @default.
• W3157727129 cites W3011494532 @default.
• W3157727129 cites W3012379316 @default.
• W3157727129 cites W3014962324 @default.
• W3157727129 cites W3015759088 @default.
• W3157727129 cites W3016395404 @default.
• W3157727129 cites W3018023298 @default.
• W3157727129 cites W3020646040 @default.
• W3157727129 cites W3021217583 @default.
• W3157727129 cites W3021847337 @default.
• W3157727129 cites W3026888299 @default.
• W3157727129 cites W3027630905 @default.
• W3157727129 cites W3029018063 @default.
• W3157727129 cites W3031460555 @default.
• W3157727129 cites W3035026987 @default.
• W3157727129 cites W3035186756 @default.
• W3157727129 cites W3035399681 @default.
• W3157727129 cites W3036691156 @default.
• W3157727129 cites W3040387082 @default.
• W3157727129 cites W3040751560 @default.
• W3157727129 cites W3046413061 @default.
• W3157727129 cites W3104644008 @default.
• W3157727129 cites W3107056972 @default.
• W3157727129 cites W3109673381 @default.
• W3157727129 cites W4210642183 @default.
• W3157727129 doi "https://doi.org/10.1016/j.clinthera.2021.04.007" @default.
• W3157727129 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8101859" @default.
• W3157727129 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34052007" @default.
• W3157727129 hasPublicationYear "2021" @default.
• W3157727129 type Work @default.
• W3157727129 sameAs 3157727129 @default.
• W3157727129 citedByCount "46" @default.
• W3157727129 countsByYear W31577271292021 @default.
• W3157727129 countsByYear W31577271292022 @default.
• W3157727129 countsByYear W31577271292023 @default.
• W3157727129 crossrefType "journal-article" @default.
• W3157727129 hasAuthorship W3157727129A5002948253 @default.
• W3157727129 hasAuthorship W3157727129A5015202852 @default.
• W3157727129 hasAuthorship W3157727129A5017719452 @default.
• W3157727129 hasAuthorship W3157727129A5031651486 @default.
• W3157727129 hasAuthorship W3157727129A5040224979 @default.
• W3157727129 hasAuthorship W3157727129A5053766617 @default.
• W3157727129 hasAuthorship W3157727129A5067263527 @default.
• W3157727129 hasAuthorship W3157727129A5084360723 @default.
• W3157727129 hasBestOaLocation W31577271291 @default.
• W3157727129 hasConcept C126322002 @default.
• W3157727129 hasConcept C168563851 @default.
• W3157727129 hasConcept C187212893 @default.
• W3157727129 hasConcept C197934379 @default.
• W3157727129 hasConcept C2777499811 @default.
• W3157727129 hasConcept C2779123688 @default.
• W3157727129 hasConcept C2779134260 @default.
• W3157727129 hasConcept C3008058167 @default.
• W3157727129 hasConcept C42972112 @default.
• W3157727129 hasConcept C524204448 @default.
• W3157727129 hasConcept C535046627 @default.
• W3157727129 hasConcept C71924100 @default.
• W3157727129 hasConceptScore W3157727129C126322002 @default.
• W3157727129 hasConceptScore W3157727129C168563851 @default.
• W3157727129 hasConceptScore W3157727129C187212893 @default.
• W3157727129 hasConceptScore W3157727129C197934379 @default.
• W3157727129 hasConceptScore W3157727129C2777499811 @default.
• W3157727129 hasConceptScore W3157727129C2779123688 @default.
• W3157727129 hasConceptScore W3157727129C2779134260 @default.
• W3157727129 hasConceptScore W3157727129C3008058167 @default.
• W3157727129 hasConceptScore W3157727129C42972112 @default.
• W3157727129 hasConceptScore W3157727129C524204448 @default.
• W3157727129 hasConceptScore W3157727129C535046627 @default.
• W3157727129 hasConceptScore W3157727129C71924100 @default.
• W3157727129 hasIssue "6" @default.
• W3157727129 hasLocation W31577271291 @default.
• W3157727129 hasLocation W31577271292 @default.
• W3157727129 hasLocation W31577271293 @default.
• W3157727129 hasOpenAccess W3157727129 @default.
• W3157727129 hasPrimaryLocation W31577271291 @default.
• W3157727129 hasRelatedWork W190931331 @default.
• W3157727129 hasRelatedWork W2109097527 @default.
• W3157727129 hasRelatedWork W2408674979 @default.
• W3157727129 hasRelatedWork W2490914975 @default.

• next